Harmony Biosciences Holdings, Inc. Stock Price, News & Analysis

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that President and CEO John C. Jacobs will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 4:30 p.m. PT / 7:30 p.m. ET. The live audio webcast of the presentation will be available on the investor page of Harmony's website. Harmony focuses on developing innovative therapies for rare neurological diseases, emphasizing the importance of empathy and innovation in improving patient lives.

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will engage in a fireside chat and individual investor meetings at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 9:00 am ET in New York, NY. A webcast of this chat will be accessible on Harmony's investor webpage. The company, based in Plymouth Meeting, PA, focuses on innovative therapies for rare neurological diseases, emphasizing patient-centric solutions since its establishment in 2017.

Harmony reported third-quarter 2022 net revenues of $117.2 million, a 45% increase from the previous year, driven by strong sales of WAKIX. The average number of patients on WAKIX rose to approximately 4,600. The company achieved a GAAP net income of $87.9 million, or $1.44 per diluted share, a significant turnaround from a net loss of $9.6 million in Q3 2021. R&D expenses surged by 245.4% to $40.5 million due to an initial licensing fee. Ongoing clinical trials show positive momentum, especially in Prader-Willi Syndrome and Idiopathic Hypersomnia.

Harmony Biosciences (Nasdaq: HRMY) announced topline results from its Phase 2 proof-of-concept study assessing pitolisant for Prader-Willi syndrome (PWS), indicating improvements in excessive daytime sleepiness (EDS). The study, involving 65 patients, reported that patients treated with high-dose pitolisant demonstrated a clinically meaningful change in ESS-CHAD scores. Despite the positive signals, the adolescent group showed a high placebo response, limiting comparisons. Safety profiles were consistent with existing data, with 57% of patients on pitolisant reporting adverse events.

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) will report its third quarter 2022 financial results on November 1, 2022, before U.S. market opening. A conference call is scheduled for the same day at 8:30 a.m. ET to discuss the results. Investors can dial (800) 225-9448 domestically or +1 (203) 518-9708 internationally to participate. Harmony focuses on innovative therapies for rare neurological diseases, emphasizing the importance of empathy and innovation in their approach.

On September 22, 2022, Harmony Biosciences (NASDAQ: HRMY) announced its 2022 funding recipients for the Patients at the Heart and Progress at the Heart award programs on World Narcolepsy Day. Over the past four years, these programs have awarded a total of $380,000 to nonprofit organizations aimed at supporting people with rare neurological diseases. Recipients this year focus on enhancing community health literacy, creating peer support initiatives, and raising awareness for sleep disorders.

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY), a pharmaceutical company dedicated to rare neurological diseases, will participate in upcoming investor conferences. These include the Wells Fargo Healthcare Conference on September 7, 2022, featuring a fireside chat at 2:35 p.m. ET and 1x1 meetings. Additionally, the Citi's 17th Annual BioPharma Conference will take place in Boston on the following day with similar 1x1 meetings. A webcast of the fireside chat will be available on Harmony's investor page.

Harmony Biosciences reported net revenue of $107.0 million for Q2 2022, up 45% from Q2 2021, driven by strong sales of WAKIX®. The average number of patients on WAKIX increased to approximately 4,300. The company also signed a new agreement with Bioprojet to develop therapeutics based on pitolisant, potentially expanding its product offerings. GAAP net income rose to $23.5 million ($0.39 per share), while total operating expenses increased by 45.4% to $55.0 million.

Harmony Biosciences Holdings, Inc. (HRMY) will release its second quarter 2022 financial results on August 2, 2022. Following the release, a conference call and live webcast will occur at 8:30 a.m. ET. Investors can join the call by dialing (800) 459-5346 for domestic or +1 (203) 518-9544 for international, referencing passcode HRMYQ222. The live and replayed webcast will be accessible on the company's investor page. Harmony focuses on developing therapies for rare neurological diseases.